Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pronethalol ((±)-Pronethalol), a non-selective β-adrenergic antagonist, effectively inhibits Sox2 expression and offers protection against Digitalis-induced ventricular arrhythmias. Additionally, it can reverse such arrhythmias and limit the development of cerebral arteriovenous malformations (AVMs) [1] [2].
Description | Pronethalol ((±)-Pronethalol), a non-selective β-adrenergic antagonist, effectively inhibits Sox2 expression and offers protection against Digitalis-induced ventricular arrhythmias. Additionally, it can reverse such arrhythmias and limit the development of cerebral arteriovenous malformations (AVMs) [1] [2]. |
In vitro | Pronethalol (2, 10, 20 μM) represses EGFP expression in a dose- and time-dependent manner in ReNcell VM cells. Pronethalol (10 μM; 2 days) reduces the expression of Sox2 to less than 10% after 2 days of treatment [2]. |
In vivo | Pronethalol (0.15 mg/g; daily; for 14 days) stabilizes endothelial differentiation, lumen formation which limits cerebral arteriovenous malformation (AVMs) in Mgp –/– mice [2]. |
Molecular Weight | 229.32 |
Formula | C15H19NO |
CAS No. | 54-80-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mM
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pronetalol 54-80-8 inhibitor inhibit